Health Care
Stocks whipsawed violently last week. Volatility could intensify if recent whiffs of a domestic economic slowdown proliferate and the Fed still adopts a more hawkish tone.
Pharmaceutical stocks are trading at historically cheap relative valuations on the back of political pressure on a few high-profile specialty pharma companies. We see this as an opportunity to add to positions in the more traditional pharma space. Our concerns about excessive drug pricing will only materialize when there is evidence that consumption patterns are changing. So far, there is scant evidence of higher prices choking consumption. Consumer spending on drugs is hitting new highs. That is true in both real and nominal terms, underscoring that higher outlays are not simply a reflection of rising drug prices. While the growth rate of drug consumption may slow, pent up demand from years of medical procedure deferral following the Great Recession will take time to play out. As such, soaring pharmaceutical shipments should be interpreted as demand-driven. Consequently, we expect profit outperformance to persist, and drive a sustained recovery in relative share prices. The ticker symbols for the stocks in this index are: BLBG: S5PHAR - JNJ, PFE, MRK, BMY, AGN, LLY, ZTS, MYL, PRGO, MNK, ENDP.
A spate of mergers in the medical equipment space has helped propel relative performance to new cyclical highs. In our latest update, we noted our expectation for another upleg, but some niggling concerns about the future revenue outlook caused us to put the group on downgrade alert. However, recent data are supportive of a continuation of the uptrend. The medical equipment shipments-to-inventory ratio is trending steadily higher. Importantly, investment in medical equipment has reaccelerated, as has new health care facility construction. That bodes well for future equipment demand, and should keep factories operating at optimal rates. Consequently, we recommend maintaining overweight positions for a while longer, especially since value is not problematic. The ticker symbols for the stocks in this index are: BLBG: S5HCEP - MDT, ABT, SYK, BDX, BSX, BAX, ISRG, EW, STJ, ZBH, BCR, HOLX, VAR.
While technology sector profits are disappointing on the back of the paucity of volume growth and deflation (i.e. INTC, IBM), the same is not true for health care companies. Several large cap health care firms have reported robust earnings results (i.e. JNJ, UNH), reflecting steady non-cyclical demand growth and burgeoning pricing power. Indeed, managed care companies are successfully lifting premiums, while pharmaceutical firms continue to enjoy nearly unprecedented pricing power (bottom panel). While the latter is a point of political contention in the U.S., history shows that it is an extremely difficult and drawn out process to effect change. In the meantime, the health care sector's ability to lift selling prices stands in stark contrast with the overall corporate sector. For instance, the small business sector is showing an inability to lift selling prices, as reflected by the NFIB reported price change series, (shown inverted, top panel), which is bordering on recessionary readings. As a result, health care profits should continue to outperform, and we reiterate our recent move to a high-conviction overweight. The ticker symbols for the stocks in this index are: BLBG: S5HLTH.
We are confident that the reward/risk tradeoff to holding equities and high-yield corporate bonds is deteriorating and that rallies in these assets are high-risk affairs.
The self-driving car, or Autonomous Vehicle (AV), will have a profound impact on a variety of industries. However, expectations for the timeframe of commercial AV availability are too optimistic. The greatest near-term impact is likely to be from advanced safety technologies developed on the path to full autonomy. In today's <i>Special Report</i>, we discuss our expectations for the timeframe of AV development, and the effect of advanced safety technologies on the Insurance, Health Care, Semiconductors, and Automotive industries.
Last week we added the overall health care sector to our high-conviction overweight list, given our confidence that defensive sectors will continue to outperform the broad market on a cyclical basis, regardless of the latter's near-term trend. As part of this move, the S&P managed care index now warrants overweight exposure. The pressure on payers of medical services relative to the providers of those services has ebbed, because overall health care outlays are no longer accelerating relative to total spending. That should open the door to another upleg in relative performance, provided costs stay under control. On this front, our medical cost proxy is still moving laterally, despite the previous increase in surgeries, procedures and sector pricing inflation. This will keep a lid on the medical loss ratio, alleviating potential downward pressure on profit margins, and by extension, relative valuations. Keep in mind that the impact of previous consolidation on cost containment has yet to be fully felt. The implication is that discount relative valuations should be exploited. Upgrade to overweight and please see yesterday's Weekly Report for more details. The ticker symbols for the stocks in this index are: BLBG: S5MANH - AET, ANTM, CNC, CI, HUM, UNH.
Equities are back in overshoot territory. We added the health care sector to our high-conviction overweight list, boosted managed care to overweight and put health care equipment on downgrade alert. Buy cable stocks.
Monday's Special Report highlighted an overwhelmingly bullish macro backdrop for defensive sector relative performance. Health care is a key defensive component, but it has been hit hard in recent weeks, denting investor confidence. The main culprits behind the pullback have been the bounce in inflation expectations on the back of the dip in the U.S. dollar. The sector had rallied in lockstep with intensifying global deflationary pressures for the past few years, and it is only natural that it be used as a source of funds to lift exposure to cyclical sectors on the first whiff of financial stress relief. However, the path of least resistance for health care earnings is still up, in relative terms. Our Cyclical Macro Indicator is emitting bullish signals, supported by the resurgence in sector pricing power, particularly compared with moribund overall corporate sector selling price inflation. Importantly, valuation and technical factors also argue for a bullish reversal. Our relative valuation gauge is at an extremely undervalued level, while technical conditions are deeply oversold. These conditions are unlikely to last if relative forward earnings keep climbing, as we expect. Consequently, the reward/risk tradeoff is sufficiently upbeat to warrant adding the sector to our high-conviction overweight list.
The S&P pharmaceutical index has checked back relative to the broad market, reflecting the powerful short covering and relief rally in higher beta sectors in recent weeks. While this trend may persist in the very near run, we expect relative performance to follow relative forward earnings growth. On this front, conditions are bullish. In absolute terms, pharmaceutical companies are enjoying a productivity revival, as a demand-driven surge in pricing power is underway. That stands in marked contrast with the rest of the corporate sector, which is battling deflation, as evidenced by the relentless decline in bond yields (shown inverted, top panel). The chart shows that when firms are cutting selling prices, pharmaceutical profits outperform, as is currently the case. Moreover, drug companies continue to use excess capital in a shareholder-friendly manner, as shares outstanding continue to sink. The bottom line is that pharmaceutical earnings are on track for further outperformance, which should pull up the share price ratio. Stay overweight. The ticker symbols for the stocks in this index are: AGN, BMY, LLY, ENDP, JNJ, MNK, MRK, MYL, PRGO, PFE, ZTS.